These findings identify SHP2 as a critical immune checkpoint regulator and a promising therapeutic target in CRC, and this SHP2-mediated suppression of efferocytosis allows tumor cells to evade immune clearance and persist within the TME, contributing to tumor progression and resistance to immunotherapy [63] (Figure 6B). Here, PTPN11 is linked to colorectal carcinoma.